507 related articles for article (PubMed ID: 25733311)
41. Nanomedicine in pulmonary delivery.
Mansour HM; Rhee YS; Wu X
Int J Nanomedicine; 2009; 4():299-319. PubMed ID: 20054434
[TBL] [Abstract][Full Text] [Related]
42. Lipid-based nanoparticle formulations for small molecules and RNA drugs.
Ickenstein LM; Garidel P
Expert Opin Drug Deliv; 2019 Nov; 16(11):1205-1226. PubMed ID: 31530041
[No Abstract] [Full Text] [Related]
43. siRNA delivery to lung-metastasized tumor by systemic injection with cationic liposomes.
Hattori Y; Nakamura A; Arai S; Kawano K; Maitani Y; Yonemochi E
J Liposome Res; 2015; 25(4):279-86. PubMed ID: 25543847
[TBL] [Abstract][Full Text] [Related]
44. A special issue on Lipid-based delivery systems (liposomes, lipid nanoparticles, lipid matrices and medicines).
Souto EB
J Biomed Nanotechnol; 2009 Aug; 5(4):315-6. PubMed ID: 20055077
[No Abstract] [Full Text] [Related]
45. In vitro optimization of liposomal nanocarriers prepared from breast tumor cell specific phage fusion protein.
Wang T; Kulkarni N; Bedi D; D'Souza GG; Papahadjopoulos-Sternberg B; Petrenko VA; Torchilin VP
J Drug Target; 2011 Sep; 19(8):597-605. PubMed ID: 21275826
[TBL] [Abstract][Full Text] [Related]
46. Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) for pulmonary application: a review of the state of the art.
Weber S; Zimmer A; Pardeike J
Eur J Pharm Biopharm; 2014 Jan; 86(1):7-22. PubMed ID: 24007657
[TBL] [Abstract][Full Text] [Related]
47. Sodium colistimethate loaded lipid nanocarriers for the treatment of Pseudomonas aeruginosa infections associated with cystic fibrosis.
Pastor M; Moreno-Sastre M; Esquisabel A; Sans E; Viñas M; Bachiller D; Asensio VJ; Pozo AD; Gainza E; Pedraz JL
Int J Pharm; 2014 Dec; 477(1-2):485-94. PubMed ID: 25445528
[TBL] [Abstract][Full Text] [Related]
48. Applications and limitations of lipid nanoparticles in dermal and transdermal drug delivery via the follicular route.
Lauterbach A; Müller-Goymann CC
Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):152-63. PubMed ID: 26144664
[TBL] [Abstract][Full Text] [Related]
49. Application of Box-Behnken design for preparation of levofloxacin-loaded stearic acid solid lipid nanoparticles for ocular delivery: Optimization, in vitro release, ocular tolerance, and antibacterial activity.
Baig MS; Ahad A; Aslam M; Imam SS; Aqil M; Ali A
Int J Biol Macromol; 2016 Apr; 85():258-70. PubMed ID: 26740466
[TBL] [Abstract][Full Text] [Related]
50. Targeted lipid nanoparticles for antisense oligonucleotide delivery.
Petrilli R; Eloy JO; Marchetti JM; Lopez RF; Lee RJ
Curr Pharm Biotechnol; 2014; 15(9):847-55. PubMed ID: 25335532
[TBL] [Abstract][Full Text] [Related]
51. The formalism of fractal aggregation phenomena of colloidal drug delivery systems.
Pippa N; Demetzos C; Danezis E
J Liposome Res; 2012 Mar; 22(1):55-61. PubMed ID: 21774618
[TBL] [Abstract][Full Text] [Related]
52. Characterization and formulation optimization of solid lipid nanoparticles in vitamin K1 delivery.
Liu CH; Wu CT; Fang JY
Drug Dev Ind Pharm; 2010 Jul; 36(7):751-61. PubMed ID: 20136495
[TBL] [Abstract][Full Text] [Related]
53. Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics.
Chen CC; Tsai TH; Huang ZR; Fang JY
Eur J Pharm Biopharm; 2010 Mar; 74(3):474-82. PubMed ID: 20060469
[TBL] [Abstract][Full Text] [Related]
54. Preparation and evaluation of lipid emulsified docetaxel-loaded nanoparticles.
Zhang F; Chang M; Yu Y; Zhang Y; Liu G; Wei T; Zuo T; Guan Y; Lin G; Zhao Z
J Pharm Pharmacol; 2015 Nov; 67(11):1546-55. PubMed ID: 26256262
[TBL] [Abstract][Full Text] [Related]
55. Second generation lipid nanoparticles (NLC) as an oral drug carrier for delivery of lercanidipine hydrochloride.
Ranpise NS; Korabu SS; Ghodake VN
Colloids Surf B Biointerfaces; 2014 Apr; 116():81-7. PubMed ID: 24445002
[TBL] [Abstract][Full Text] [Related]
56. Lipid-based nanocarriers for drug delivery and targeting: a patent survey of methods of production and characterization.
Carbone C; Cupri S; Leonardi A; Puglisi G; Pignatello R
Pharm Pat Anal; 2013 Sep; 2(5):665-77. PubMed ID: 24237173
[TBL] [Abstract][Full Text] [Related]
57. Enhancing the pharmacokinetic/pharmacodynamic properties of therapeutic nucleotides using lipid nanoparticle systems.
Lin PJ; Tam YK
Future Med Chem; 2015; 7(13):1751-69. PubMed ID: 26399560
[TBL] [Abstract][Full Text] [Related]
58. Ternary nanoparticles of anionic lipid nanoparticles/protamine/DNA for gene delivery.
Yuan H; Zhang W; Du YZ; Hu FQ
Int J Pharm; 2010 Jun; 392(1-2):224-31. PubMed ID: 20230883
[TBL] [Abstract][Full Text] [Related]
59. Enhanced systemic exposure of fexofenadine via the intranasal administration of chitosan-coated liposome.
Qiang F; Shin HJ; Lee BJ; Han HK
Int J Pharm; 2012 Jul; 430(1-2):161-6. PubMed ID: 22525082
[TBL] [Abstract][Full Text] [Related]
60. Construction and comparison of different nanocarriers for co-delivery of cisplatin and curcumin: A synergistic combination nanotherapy for cervical cancer.
Li C; Ge X; Wang L
Biomed Pharmacother; 2017 Feb; 86():628-636. PubMed ID: 28027539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
